Nearly all the patients had Type 2 diabetes. Over three years, researchers tracked those who were prescribed either a GLP-1 drug like Ozempic or an SGLT2 medication like Jardiance after their initial ...

Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may protect the kidneys better than glucagon-like peptide 1 receptor ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

On Thursday, members of the Endocrinologic and Metabolic Drugs Advisory Committee will help the FDA decide whether the ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

A recent case report highlights the importance of understanding the possibility of the development of Euglycemic diabetic ...

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

A collaboration of researchers led by Emory University Rollins School of Public Health, Atlanta, is urging caution when ...